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EDITORIAL
Vitamin  D as  a  modiﬁable  risk factor  in critical  illness: questions
and answers  provided  by  observational  studies,
Vitamina  D  como  um  fator  de  risco  modiﬁcável  em  doenc¸as  graves:
perguntas  e  respostas  de  estudos  observacionais
J. Dayre McNallyDepartment  of  Pediatrics,  Faculty  of  Medicine,University  of  Ottawa;  Children’s  Hospital  of  Eastern  Ontario,  Ottawa,  Canada
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iVitamin  D  is  essential  to  optimal  health.  Studies  dating
back to  the  early  1900’s  convincingly  demonstrate  that
a state  of  vitamin  D  deﬁciency,  acquired  through  limited
sun exposure  and  avoidance  of  vitamin  D-rich  foods  can
lead to  stunted  growth,  bone  disease,  and  hypocalcemic
seizures. Over  the  past  few  decades,  a  rising  body  of  epi-
demiological literature  has  also  suggested  that  vitamin  D
deﬁciency predisposes  to  a  wide  variety  of  disease  states
outside of  the  musculoskeletal  system.  For  example,  vita-
min D  status  has  been  associated  with  diseases  involving
dysregulation of  the  immune  (type  I  diabetes,  cancer),  car-
diovascular (heart  failure,  cardiomyopathy),  and  respiratory
systems (bronchiolitis,  pneumonia).  Strong  biological  plau-
sibility  supporting  these  epidemiological  ﬁndings  has  been
provided, including  basic  science  studies  showing  the  pres-
ence of  vitamin  D  receptors  on  a  large  number  of  diverse  cell
types  (e.g.  white  blood  cells,  myocytes),  and  animal  studies
demonstrating disease  occurrence  in  genetically-  (vitamin  D
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iency states.
As the  pathophysiology  of  the  immune,  cardiovascular,
espiratory, and  renal  systems  is  central  to  critical  illness,
t is  not  surprising  that  clinicians  and  researchers  have  also
ypothesized that  vitamin  D  may  be  a  modiﬁable  risk  factor
n the  intensive  care  setting.  Since  the  initial  NEJM  pub-
ication in  2009  by  Lee  et  al.,1 there  have  been  dozens
f adult  epidemiological  studies  on  this  subject,  and  the
verwhelming majority  reported  high  vitamin  D  deﬁciency
ates and  statistical  relationships  with  illness  severity.  In
he adult  realm,  interventional  studies  are  underway,  with
he publication  of  two  pilot  phase  II  studies  evaluating  rapid
estoration regimens2,3 and  the  initiation  of  a large  random-
zed controlled  trial.4
In  comparison,  the  importance  of  vitamin  D  in  pediatric
ritical illness  is  signiﬁcantly  less  studied,  and  the  publi-
ation by  Rey  et  al.  in  this  issue5 adds  to  this  emerging
ody of  literature.  Notwithstanding  the  publication  by  Rey
t al.  the  pediatric  literature  on  vitamin  D  in  critically  ill
hildren was  summarized  in  a  recent  review.6 The  initial
ediatric studies  addressing  this  question  were  published  in
ate 2012.7,8 Including  the  publication  by  Rey  et  al.,  there
re now  two  studies  on  mixed  medical/surgical  populations,
wo on  isolated  medical  populations,  and  two  on  isolated
ardiac surgery  populations.5,7--11 Although  some  variability
as observed,  all  studies  report  clinically  signiﬁcant  vita-
in D  deﬁciency  prevalence  rates  (30%  to  80%).  The  four
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tudies  involving  post-operative  cardiac  surgery  patients
eported statistically  signiﬁcant  relationships  between  low
5-hydroxyvitamin D  (25OHD)  and  greater  illness  severity.
he picture  is  less  clear  for  the  studies  on  pediatric  intensive
are unit  populations,  with  only  two  of  the  four  studies  docu-
enting such  a  statistically  signiﬁcant  association.  Although
he most  recent  study  by  Rey  et  al.  did  not  present  any  sta-
istically signiﬁcant  associations,  there  were  some  potential
rends noted,  and  the  study  was  at  risk  for  type  II  error  given
he small  sample  size  and  unadjusted  analysis.
Does  the  optimization  of  vitamin  D  status  prevent  or
peed recovery  from  pediatric  critical  illness?  Multiple
esearch groups,  most  recently  Rey  et  al.,  have  performed
he standard  initial  studies  used  to  answer  research  ques-
ions of  this  variety.  An  evaluation  of  the  available  studies
emonstrates that,  regardless  of  geography,  many  critically
ll children  are  vitamin  D  deﬁcient.  This  observation  would
ppear to  present  an  opportunity.  The  missing  information
s whether  and  to  what  extent  the  natural  history  of  dis-
ase is  modiﬁed  by  raising  vitamin  D  levels.  Observational
tudies on  nutrients  and  hormones  are  often  used  to  pre-
ict the  potential  magnitude  of  effect  by  comparing  illness
ourse in  groups  of  patients  with  different  levels.  Regard-
ess of  whether  the  results  show  the  desired  associations,
linicians and  researchers  struggle  to  interpret  and  compare
he ﬁndings  from  both  singular  and  groups  of  observational
tudies. This  is  due  to  small  sample  size,  patient  hetero-
eneity (within  and  between  studies),  measurement  error,
onfounding factors,  outcome  selection,  statistical  analysis,
nd reporting  biases.  In  addition  to  the  standard  problems
ssociated with  PICU  studies  of  this  nature,  there  are  other
roblems speciﬁc  to  vitamin  D  that  further  complicates  the
ssue. First,  although  recognized  as  the  appropriate  marker
f vitamin  D  status  in  most  populations,  25OHD  levels  may
ot accurately  reﬂect  body  stores  in  critically  ill  patients
those with  hypoparathyroidism,  renal  dysfunction,  inter-
titial leak  of  binding  proteins,  ﬂuid  shifts,  dialysis).  It  has
een suggested  that  blood  concentrations  of  the  active  vita-
in  D  hormone  might  better  reﬂect  vitamin  D  axis  function,
 question  that  will  require  further  studies,  which  will  also
uffer from  the  abovementioned  problems.  Second,  asso-
iation studies  intended  to  evaluate  and  demonstrate  that
igher vitamin  D  levels  prevent  illness  or  speed  recovery
uffer from  a  lack  of  patients  with  blood  25OHD  levels  that
epresent the  target.  Stated  differently,  it  is  not  possible  to
stimate the  beneﬁts  of  a  25OHD  level  of  100  nmol/L  when
ew of  the  study  participants  achieve  this  target.
What  advice  should  be  given  regarding  vitamin  D  supple-
entation to  clinicians  who  care  for  patients  who  are
ither at  risk  for  critical  illness  or  are  critically  ill?  For
ow, it  would  appear  prudent  to  provide  pre-illness  supple-
entation in  a  range  known  to  safely  maintain  25OHD  at
00 nmol/L  (1,000  to  2,000  IU/day).12,13 There  are  speciﬁc
opulations that  deserve  special  attention  and  may  require
igher supplementation  doses  to  achieve  desired  vitamin
 status  (patients  with  renal  dysfunction,  malabsorp-
ion syndromes,  anti-seizure  medications,  cardiopulmonary
ypass).14,15 With  good  compliance,  a  daily  intake  in  the
,000 to  4,000  IU  range  for  two  to  three  months  should
chieve target  vitamin  D  levels.  An  alternative  approach  is
equired to  optimize  vitamin  D  status  in  the  actively  criti-
ally ill  patients  who  are  vitamin  D  deﬁcient.  What  is  clear
1McNally  JD
s  that  daily  administration  of  low  dose  vitamin  supplemen-
ation (400  to  4,000  IU/day)  will  not  restore  levels  in  a
eneﬁcial time  frame.  Instead,  clinicians  will  need  to  con-
ider loading  doses  (or  stoss  therapy)  ranging  from  50,000
o 600,000  IU,  depending  on  starting  level  and  weight.16--18
iven  evidence  (albeit  largely  from  case  reports/series)
hat high  doses  may  cause  hypercalcemia,  hypercalciuria,
r nephrocalcinosis,  vitamin  D  loading  doses  cannot  be  rec-
mmended in  critically  ill  children  without  clinical  trial
ata.19,20 As  such,  the  next  steps  in  this  emerging  ﬁeld  are
atience (results  of  the  adult  stoss  therapy  randomized  clini-
al trials)  and  completion  of  smaller  phase  II  dose-evaluation
tudies in  children.
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